Navigation Links
Syncope and implantable loop recorders: Good value for money?
Date:9/1/2009

Barcelona, Spain, 1 September 2009: The REVISE Study (Reveal in the Investigation of Syncope and Epilepsy) found that 1 in 8 adult patients in the United Kingdom, previously thought to be suffering from epilepsy or in whom this diagnosis was in doubt, in fact had symptoms as a result of an abnormal pattern of heart beating, commonly found in patients with syncope (fainting).

REVISE is the first study to show that, by means of an implantable ECG recorder, 1 in 8 patients who were previously thought to have epilepsy or in whom this diagnosis was in doubt, have an abnormality in their heart rhythm as a cause of their symptoms. Eighty percent of those who underwent a pacemaker insertion based on the results of the ECG loop recorder were subsequently found to be free of their symptoms.

Four of the 5 patients who underwent a pacemaker as part of this study were subsequently free of symptoms. The average duration of follow-up was 9 months. This study was carried out at the Manchester Heart Centre, Manchester Royal Infirmary, Manchester, UK in collaboration with the Greater Manchester Centre for Neurosciences, Hope Hospital, Salford, UK. A small metallic device * about the size of a memory stick or a packet of gum, was used to record the heart rhythm of patients in this study. This device was inserted underneath the skin, on the left side of the chest in a small, low risk, 20 minute operation. Study patients also underwent a number of other brain and heart tests.

Previous scientific studies, mainly from the United Kingdom, have shown that up to 1 in 4 patients thought to be suffering from epilepsy do not actually have this condition. This conclusion was based on reviewing medical records of patients known to have epilepsy and on the results of the tilt table test, a test in which patients are made to stand at an angle of 60 degrees on a bed with a footboard support in an attempt to induce a blackout. Moreover, the All Party Parliamentary Group on Epilepsy, in their report published in June 2007, found that 74,000 patients in the United Kingdom were taking drugs for epilepsy, which they did not need. Patients with syncope (fainting) as well as epilepsy present with transient loss of consciousness (T-LOC) or 'blackouts'. In some patients syncope (fainting) can mimic epilepsy. A temporary decrease in blood supply to the brain which occurs in syncope (fainting) can result in irritation of brain cells causing abnormal movements, which to a lay person can look very similar to epilepsy. In the general population, syncope (fainting) is much more common than epilepsy, affecting 25% of the population at any given time, more so in the elderly.

Patients symptomatic with T-LOC/'blackouts' were considered for inclusion in this study if on review by the neurologists there was a suspicion of misdiagnosis of epilepsy or there was a doubt regarding the diagnosis. Patients had to have suffered at least 3 blackouts in the year before enrolment. In addition, they had to have had a normal or equivocal recording of their heart rhythm (standard ECG and an external recording for at least 24 hours), brain waves (EEG), a scan of the heart (echocardiogram) and of the brain (CT scan or MRI). Once included, all patients underwent a Reveal Plus/Reveal DX implant for monitoring their heart rhythm and tilt table testing. The study protocol allowed for treatment, based on the results of the implantable ECG monitor. The main aim of the study was to record the heart rhythm at the time of the patients symptoms of T-LOC/blackouts by means of the implantable ECG monitor. This study also aimed to determine the value of the tilt table test, a test commonly used in the investigation of patients with T-LOC/blackouts, in this group of patients.

Of the 119 patients screened, 40 were found suitable for inclusion in the study. Two thirds of patients were females and the average age was 39 years. The oldest patient in the study was 80 years of age. The implantable ECG monitor recorded a heart rhythm at the time of symptoms in two thirds of patients. Six patients were found to have an abnormal heart rhythm, viz. severe slowing of the heart beats, to the point of an absent heart rhythm, for a few seconds. In four other patients, the heart rhythm was found to slow but not as severely as the previous group. In 4 others, the implantable ECG monitor recorded signals due to muscle shaking in a pattern commonly seen in patients with epilepsy, thus giving the doctors a clue to the diagnosis. All but one of the six patients with severe slowing of the heart beats underwent a pacemaker. Four of the five (80%) who had pacemakers were subsequently free of symptoms over the following 9 months. Tilt table testing was positive in 5 of 40 patients. None of the patients with a positive tilt table test showed severe slowing of the heart rhythm on the implantable ECG monitor.

REVISE is the first study to show, that by means of an implantable ECG recorder, 1 in 8 patients who were previously thought to have epilepsy or in whom this diagnosis was in doubt, have an abnormality in their heart rhythm as a cause of their symptoms. Eighty percent of those who underwent a pacemaker insertion based on the results of the ECG loop recorder were subsequently found to be free of their symptoms. The implantable ECG loop recorder was also helpful in pointing towards a diagnosis of epilepsy by the pattern of the signals recorded on it. The findings of this small study will need confirmation in a larger group of patients.


'/>"/>

Contact: Jacquelline Partarrieu
jpartarrieu@escardio.org
0034-600-919-617
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM))
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. MITs implantable device offers continuous cancer monitoring
5. FDA Advisory Panel Recommends Approval of VisionCares Implantable Telescope for End-Stage Macular Degeneration
6. Honolulu Opthalmologist Alan R. Faulkner, MD Discusses Advantages of Implantable Contact Lenses (ICL) over LASIK Laser Vision Correction
7. Access MediQuip and WellPoint Finalize First National Contract for Implantable Medical Devices
8. Implantable monitor may help in managing diastolic heart failure
9. MP3 headphones interfere with implantable defibrillators, pacemakers
10. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
11. Texcel Introduces Innovative Programmable, Implantable Stimulation System for R&D of Specialty Stimulation Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
(Date:12/2/2016)... SAN DIEGO, Calif. (PRWEB) , ... December 02, 2016 , ... ... Recognition Event at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight ... as myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  PipelineRx, a leading medication management ... offering demonstrations of its SaaS-based telepharmacy platform, ... Pharmacists 2016 Midyear Clinical Meeting and Exhibition, December ... With nearly 300 hospital clients nationally, the Company ... designed to dramatically improve pharmacy operations, enhance patient ...
(Date:12/2/2016)... -- On Thursday, December 1st 2016, the ... development and innovation in the biopharmaceutical industry at its ... the presence of Sergey Tsyb, Vice Minister of Industry ... , Natalia Sanina, First Vice Chairman of the State ... Roszdravnadzor, National Service of Control in Healthcare, Sergey Muravev, ...
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
Breaking Medicine Technology: